Novartis and Incyte are planning to launch a clinical study to test the potential of Jakavi (ruxolitinib) in patients with COVID-19 associated cytokine storm, a type of severe immune overreaction that can result from the infection and may contribute to respiratory compromise in some patients.
According to the Swiss drugmaker, preclinical and preliminary clinical evidence suggests that the JAK inhibitor could reduce the number of patients requiring intensive care and mechanical ventilation.
Phase III Trial
Research referenced in the above article.
Disclaimer: This is a guest post and it doesn’t represent the views of IWB.